PHARMACEUTICAL COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION COMPRISING AN ANTIBACTERIAL AGENT AND AN ANTIINFLAMMATORY AGENT

(19)

(11)

EP 3 024 475 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	18.11.2020 Bulletin 2020/47

(45)	Mention of the grant of the patent:
	30.09.2020 Bulletin 2020/40

(21)	Application number: 14721688.1

(22)	Date of filing: 27.03.2014

(51)

International Patent Classification (IPC):

A61K 31/4709^(2006.01)
A61K 31/573^(2006.01)
A61K 45/06^(2006.01)
A61K 38/14^(2006.01)
A61P 31/04^(2006.01)
A61P 29/00^(2006.01)

A61K 31/496^(2006.01)
A61K 31/58^(2006.01)
A61K 9/00^(2006.01)
A61P 27/02^(2006.01)
A61P 31/00^(2006.01)

(86)	International application number:
	PCT/US2014/032026

(87)	International publication number:
	WO 2015/012899 (29.01.2015 Gazette 2015/04)

(54)

PHARMACEUTICAL COMPOSITIONS FOR INTRAOCULAR ADMINISTRATION COMPRISING AN ANTIBACTERIAL AGENT AND AN ANTIINFLAMMATORY AGENT

PHARMAZEUTISCHE ZUSAMMENSETZUNGEN ZUR INTRAOKULAREN VERABREICHUNG ENTHALTEND EINEN ANTIBAKTERIELLEN UND EINEN ENTZÜNDUNGSHEMMENDEN WIRKSTOFF

COMPOSITIONS POUR UNE ADMINISTRATION INTRAOCULAIRE COMPRENANT UN AGENT ANTIBACTÉRIEN ET UN AGENT ANTI-INFLAMMATOIRE

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

22.07.2013 US 201361958170 P

(43)	Date of publication of application:
	01.06.2016 Bulletin 2016/22

(73)	Proprietors:
	Novel Drug Solutions LLC Randolph, NJ 07869 (US) Eye Care Northwest , PA Sparta, NJ 07871 (US)

(72)	Inventors:
	LIEGNER, Jeffery T. Newton, New Jersey 07860 (US) KAROLCHYK, John Scott Lake Hopatcong, New Jersey 07849 (US) COVALESKY, Bernard Randolph, New Jersey 07869 (US) DILZER, Richard Long Valley, New Jersey 07853 (US) PETERS, Kallan Flemington, New Jersey 08822 (US)

(74)	Representative: Lee, Nicholas John
	Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL London WC1X 8NL (GB)

(56)

References cited: :

WO-A2-2011/049958

Maxine Lipner: "Perioperative pharmacology. Bucking the drop trend", , May 2012 (2012-05), XP002727264, Retrieved from the Internet: URL:http://eyeworld.org/article-bucking-th e-drop-trend [retrieved on 2014-07-17]
Liegner ET AL: "Transzonular Intravitreal Injection of Triamcinolone and Moxifloxicin After IOL Insertion in Lieu of Preop/Postop Eyedrops", , 24 April 2012 (2012-04-24), XP054975453, Retrieved from the Internet: URL:http://ascrs2012.conferencefilms.com/a tables.wcs?entryid=100047 [retrieved on 2014-07-16]
MANGAN ET AL: "No endophthalmitis seen in case series of 'no-drop' cataract surgery", PRIMARY CARE OPTOMETRY NEWS,, vol. 18, no. 7, 1 July 2013 (2013-07-01), page 16, XP009179126,
PAGANELLI FERNANDO ET AL: "A single intraoperative sub-tenon's capsule injection of triamcinolone and ciprofloxacin in a controlled-release system for cataract surgery.", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE JUL 2009, vol. 50, no. 7, July 2009 (2009-07), pages 3041-3047, XP002727265, ISSN: 1552-5783
Diane Angelucci: "Intracameral injection studied to replace post-op eyedrops", , January 2006 (2006-01), XP002727322, Retrieved from the Internet: URL:http://www.eyeworld.org/article.php?si d=2918 [retrieved on 2014-07-16]
ERMIS SITKI SAMET ET AL: "Treatment of Staphylococcus epidermidis endophthalmitis with intravitreal moxifloxacin in a rabbit model", TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, vol. 205, no. 3, March 2005 (2005-03), pages 223-229, XP002727266, ISSN: 0040-8727
WISKUR BRANDT J ET AL: "Toward improving therapeutic regimens for Bacillus endophthalmitis.", INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE APR 2008, vol. 49, no. 4, April 2008 (2008-04), pages 1480-1487, XP002727267, ISSN: 0146-0404
SAKALAR YILDIRIM BAYEZIT ET AL: "Treatment of experimental Bacillus cereus endophthalmitis using intravitreal moxifloxacin with or without dexamethasone.", JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS : THE OFFICIAL JOURNAL OF THE ASSOCIATION FOR OCULAR PHARMACOLOGY AND THERAPEUTICS DEC 2011, vol. 27, no. 6, December 2011 (2011-12), pages 593-598, XP002727268, ISSN: 1557-7732
KUMAR BALAKRISHNA VINEETH ET AL: "Trans-zonular delivery of intravitreal triamcinolone acetonide in the management of pre-existing macular oedema during cataract surgery.", ACTA OPHTHALMOLOGICA SCANDINAVICA JUN 2006, vol. 84, no. 3, June 2006 (2006-06), pages 438-440, XP002727269, ISSN: 1395-3907
RICHARD MANGAN: "Transzonular injection reduces need for post-operative eye drops", , 13 August 2013 (2013-08-13), XP002727270, Retrieved from the Internet: URL:http://nebraska.aoa.org/Documents/NE/F allConvention/OD/LenticularCOMNGTRIMOX2013 BW.pdf [retrieved on 2014-07-16]


	Remarks:
	The file contains technical information submitted after the application was filed and not included in this specification

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).